// App-Quantinova.ai

: Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD

Researchers

Presenter

  • Frank Sciurba

Principal Investigators

  • Pascal Chanez

  • Jean-Benoit Martinot

  • Njira Lugogo

  • Steven W Yancey

  • Stephanie Schweiker Harris

  • Bhabita Mayer

  • Eric S Bradford

  • Frank C Albers

  • David B Rubin

Medical Centers

  • Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States

  • Department of Respiratory Medicine, Aix-Marseille University, Marseille, France

  • Department of Pneumology, CHU UCL Namur, Namur, Belgium

  • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University, Durham, United States of America

  • Respiratory Therapeutic Area, GSK, Research Triangle Park, North Carolina, United States of America

  • Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom,

  • Respiratory Medical Franchise, GSK, Research Triangle Park, NC, United States,

Locations

  • United States

  • France

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02105948

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved